Brent Sabatini was named Chief Accounting Officer of Vir Biotechnology, Inc., effective August 3, 2026. As of November 7, 2026, Vir Biotechnology, Inc. has reported 6 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 10, 2026 to October 28, 2026, naming 1 appointment and 1 departure (Form 8-K, July 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vir Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-28
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-01
- · In / out: In · Person: Brent Sabatini · Role: Chief Accounting Officer · Effective: 2026-08-03 · 8-K, 2026-07-24
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-10
- · In / out: Out · Person: Saira Ramasastry · Role: Director · Effective: 2026-05-26 · 8-K, 2026-05-28
Vir Biotechnology, Inc. reported changes in 6 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-10 to 2026-10-28. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Vir Biotechnology, Inc. files it.
Also on the record for Vir Biotechnology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13D/A, by ARCH Venture Fund IX, L.P. | 7.3% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 12.4% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.9% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 6.85% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by SB Investment Advisers (UK) Limited | 6.5% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.79% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13D/A, by ARCH Venture Fund IX, L.P. | 8.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by SB Investment Advisers (UK) Limited | 9.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vir Biotechnology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vir Biotechnology, Inc. and the records around it.
Vir Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Sana Biotechnology, Inc. (Aug 2026), Lyell Immunopharma, Inc. (May 2026)
- SB Investment Advisers (UK) Limited also filed stake reports on 5 other companies: Energy Vault Holdings, Inc. (May 2026), Compass, Inc. (Feb 2026), Roivant Sciences Ltd. (Feb 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch Vir Biotechnology, Inc.
Get an email when Vir Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vir Biotechnology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vir Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vir Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | Reported | not named in the filing | 8-K, 2026-10-28 | ||
| 2026-10-01 | Reported | not named in the filing | 8-K, 2026-10-01 | ||
| 2026-07-24 | In | Chief Accounting Officer | 2026-08-03 | 8-K, 2026-07-24 | |
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 | ||
| 2026-05-28 | Out | Director | 2026-05-26 | 8-K, 2026-05-28 | |
| 2026-04-10 | Reported | not named in the filing | 8-K, 2026-04-10 |
Who leads Vir Biotechnology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Brent Sabatini, appointed, effective 2026-08-03 (filed 2026-07-24).
- Director: Saira Ramasastry, departure reported, effective 2026-05-26 (filed 2026-05-28). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Vir Biotechnology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Vir Biotechnology, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Vir Biotechnology, Inc.Every change, in the filing's words
Reported
On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Dr. Topalian to the Science and Technology Committee of the Board, in each case effective as of October 27, 2026.
- Pursuant to the automatic grant program under such policy, on her appointment date, Dr. Topalian was granted stock option and restricted stock unit awards under the Company's 2019 Equity Incentive Plan, each in the amounts set forth and subject to vesting and other terms as provided for in the policy.
Reported
On October 1, 2026, Vir Biotechnology, Inc. (the Company) announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice President and Chief Financial Officer and "principal financial officer" of the Company, effective as of October 5, 2026 (the Effective Date).
- As of the Effective Date, Brent Sabatini, CPA, MBA, will cease serving as the Company's interim principal financial officer and continue in his role as Senior Vice President and Chief Accounting Officer and "principal accounting officer" of the Company.
- Mr. Sawaf, 44, served as Chief Financial Officer since 2023 and also Senior Vice President of Operations Strategy since 2025 at Theravance Biopharma, Inc. (Theravance).
- He first joined Theravance in 2014, holding financial leadership roles of increasing responsibility before being appointed Chief Financial Officer.
- Prior to Theravance, Mr. Sawaf held roles on the R&D and commercial finance teams at Gilead Sciences, Inc. He received a B.S. in Business Administration from the University of Arizona, an MBA from the University of Southern California, Marshall School of Business and an MBEE from Johns Hopkins University.
- Mr. Sawaf's annualized base salary will be $520,000, and he is eligible to participate in the Company's annual bonus plan with a target bonus of 45% of his annualized base salary.
- Mr. Sawaf will receive a one-time cash sign-on bonus of $150,000, one-half of which will be paid on or around the Effective Date, and one-half of which will be paid following the one-year anniversary of the Effective Date, subject to Mr. Sawaf's continued employment with the Company through each such date.
Appointed: Brent Sabatini, Chief Accounting Officer, effective 2026-08-03
Additionally, on July 23, 2026, the Board of Directors of Vir Bio appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim "principal financial officer" of Vir Bio, effective August 3, 2026.
- On July 20, 2026, Jason O'Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity.
- Mr. O'Byrne's resignation was not because of any disagreement with Vir Bio on any matter relating to Vir Bio's operations, policies, or practices.
- Vir Bio has initiated a search for his successor.
- Mr. Sabatini, 52, has served as the Senior Vice President and Chief Accounting Officer of Vir Bio since February 2023 and as the "principal accounting officer" of Vir Bio since October 2024.
- He has more than two decades of relevant experience; previously, from March 2021 to February 2023, he was at Capsida Biotherapeutics, Inc., most recently as Head of Finance.
- Prior to that, Mr. Sabatini was at Amgen Inc. from April 2004 to March 2021 where he progressed through various positions of increasing responsibility, including leadership roles in Accounting, Tax and Financial Planning and Analysis.
- Mr. Sabatini is a Certified Public Accountant and received a B.S. in Accountancy from California State University, Northridge and an MBA from the University of Michigan's Stephen M. Ross School of Business.
Reported
On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.
- Pursuant to the automatic grant program under such policy, on his appointment date, Mr. Coughlin was granted stock option and restricted stock unit awards under the Company's 2019 Equity Incentive Plan, each in the amounts set forth and subject to vesting and other terms as provided for in the policy.
Departing: Saira Ramasastry, Director, effective 2026-05-26
On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company's Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.
- Ms. Ramasastry's decision to step down from the Board is not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board expresses its appreciation for Ms. Ramasastry's service as a director and contributions to the Board and the Company.
- On May 26, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board approved the appointment of Robert More, MBA as Chair of the Audit Committee and a decrease in the size of the Board from eight to seven members, each effective upon Ms. Ramasastry's departure from the Board.
Reported
On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026.
- The Company has initiated a search for his successor.
Tools for this story
Each opens in a new tab, filled in for Vir Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.